Intratumoral serotonin and antidepressants in glioblastoma patients: narrowing the uncertainties - Takeaways - MDSpire

Intratumoral serotonin and antidepressants in glioblastoma patients: narrowing the uncertainties

  • By

  • Wendy Yi-Ying Wu

  • Barbro Numan Hellquist

  • Beatrice Melin

  • Benny Björkblom

  • Rickard L. Sjöberg

  • June 30, 2026

  • 0 min

Share

  • 1

    Glioblastoma has a five-year survival rate of approximately 5% despite surgery and radiochemotherapy.

  • 2

    Antidepressant use is more prevalent among glioma patients compared to the general population.

  • 3

    Preclinical studies suggest certain antidepressants may inhibit glioma cell growth, but clinical evidence is mixed.

  • 4

    A large cohort study indicated that overall antidepressant use was associated with worse survival in glioblastoma patients.

  • 5

    The study aims to clarify the relationship between antidepressant use, intratumoral serotonin levels, and clinical outcomes in glioblastoma.

Original Source(s)

Intratumoral serotonin and antidepressants in glioblastoma patients: narrowing the uncertainties

  • by Wendy Yi-Ying Wu, Barbro Numan Hellquist, Beatrice Melin, Benny Björkblom, Rickard L. Sjöberg

  • June 30, 2026

Related Content

Macrophage polarization in gynecologic malignancies: key signaling pathways and clinical perspectives

Primary classical Hodgkin lymphoma of breast presenting as recurrent breast abscess in a non-lactating woman: a case report and literature review

Clear cell renal cell carcinoma presenting as isolated symptomatic lumbar vertebral metastasis: a case report